Skip to main content

Advertisement

Table 2 Dose of anti-IL drug, acute phase reactants, physician assessment of disease and response to treatment at last follow-up on treatment with Canakinumab and at the moment of anakinra withdrawal

From: The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age

  Last follow-up on canakinumab Last follow-up on anakinra
Patient number Dose, mg (mg/Kg)/frequency CRP, mg/dl SAA, mg/l Clinical assessment Response Dose. mg (mg/kg)/frequency CRP, mg/dl SAA mg/l Clinical assessment Response
11 300 (4.30)/5 wks 1.17 29.9 mild partial 75 (1.30)/day 0.61 25.0 absent partial
21 150 (4.00)/6 wks 1.18 ND moderate inadequate 75 (2.00)/day neg 18.0 absent partial
31 300 (5.90)/6 wks 2.67 18.1 absent partial 100 (1.80)/day 0.47 7.50 absent partial
41 150 (2.80)/6 wks neg neg absent complete 100 (2.00)/day neg neg minimal complete
52 78 (2.00)/8 wks neg neg absent complete 55 (2.00)/day neg neg minimal complete
62 300 (3.75)/7 wks 0.57 6.5 absent partial 100 (1.16)/day 0.63 neg mild partial
71 300 (3.70)/4 wks 1.20 64.0 mild partial 100 (1.30)/day 0.73 neg absent partial
82 150 (2.30)/6 wks neg neg absent complete ND ND ND ND ND
92 150 (2.40)/8 wks neg neg absent complete 50 (1.00)/day neg neg absent complete
102 100 (2.00)/8 wks neg neg absent complete 20 (0.66)/day neg neg absent complete
111 60 (2.00)/7 wks neg neg absent complete 23 (1.00)/day neg 13.2 mild partial
121 150 (2.00)/8 wks neg neg absent complete 55 (1.00)/day neg neg absent complete
132 78 (2.00)/10 wks neg neg absent complete 38 (1.00)/day neg neg absent complete
  1. 1Patients with the chronic infantile neurological cutaneous and articular syndrome (CINCA) phenotype; 2patients with the Muckle-Wells syndrome (MWS) and MWS/CINCA phenotype; CRP, C reactive protein; SAA, serum amyloid A; neg, negative; ND, not done.